Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison. (PubMed, Acta Haematol) - Oct 8, 2026 - "Oral HMAs demonstrated cytopenia severity and adverse event rates comparable to IV HMAs, supporting oral formulations as a practical alternative in patients with MDS and AML. Although encouraging, these findings should be interpreted in the context of the retrospective design and modest sample size."
Journal • Real-world evidence • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
|
|
Catherine Lai; Chetan Jeurkar; Eesha Balar; Gina Keiffer; Jason Chen; Julia Palecki; Jun Choi; Lindsay Wilde; Margaret T Kasner; Maya Rosenberg; Niti Patel; Reed Alexander Firestone; Xiaoying Zheng
|